These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3416554)

  • 21. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama.
    Jorge LF; Arias TD; Inaba T; Jackson PR
    Br J Clin Pharmacol; 1990 Aug; 30(2):281-5. PubMed ID: 2206790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mephenytoin hydroxylation in the Cuna Amerindians of Panama.
    Inaba T; Jorge LF; Arias TD
    Br J Clin Pharmacol; 1988 Jan; 25(1):75-9. PubMed ID: 3370193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of polymorphism of sparteine oxidation in the South African Venda.
    Sommers DK; Moncrieff J; Avenant JC
    Hum Exp Toxicol; 1991 May; 10(3):175-8. PubMed ID: 1678945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sparteine metabolism in a Nigerian population.
    Ritchie JC; Mitchell SC; Smith RL
    Drug Metabol Drug Interact; 1996; 13(2):129-35. PubMed ID: 8905244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between paroxetine and the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
    Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
    Horai Y; Ishizaki T; Eichelbaum M; Hashimoto K; Chiba K; Dengler HJ
    Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine.
    Park BK; Eichelbaum M; Ohnhaus EE
    Br J Clin Pharmacol; 1982 May; 13(5):737-40. PubMed ID: 7082544
    [No Abstract]   [Full Text] [Related]  

  • 33. The genetic polymorphism of sparteine metabolism.
    Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
    Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of enzyme induction on polymorphic sparteine oxidation.
    Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
    Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
    Kaneko K; Atsumi T; Miyataka T
    Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Migration and genetic infrastructure of the Central American Guaymi and their affinities with other tribal groups.
    Barrantes R; Smouse PE; Neel JV; Mohrenweiser HW; Gershowitz H
    Am J Phys Anthropol; 1982 Jun; 58(2):201-14. PubMed ID: 6180642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.
    Klotz U; Mikus G; Zekorn C; Eichelbaum M
    Br J Clin Pharmacol; 1986 Nov; 22(5):618-20. PubMed ID: 3790411
    [No Abstract]   [Full Text] [Related]  

  • 39. Thin-layer chromatographic screening test for polymorphic sparteine oxidation.
    Ebner T; Meese CO; Eichelbaum M
    Ther Drug Monit; 1989; 11(2):214-6. PubMed ID: 2718225
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
    Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.